Calando Formally Names Cancer as First Pipeline Program; Inks IP Licensing Deal with Alnylam

/Home/Biologics Delivery - Protein Synthesis/RNA - Protein Synthesis/RNAi - Protein Synthesis

Calando Formally Names Cancer as First Pipeline Program; Inks IP Licensing Deal with Alnylam
By Doug Macron
September 7, 2006
RNAi News
Calando?s decision to pursue oncology comes as no surprise given the company?s long-standing interest in the disease, and puts the company on track to possibly become the first to test an RNAi cancer therapy in humans.
Paid subscription is required to view article.